On behalf of IFARA, Fred Schaich spoke with Glenda Gray about country-specific HIV vaccine research presented at this year's International AIDS Conference and the real-world problems that must be overcome.
On behalf of IFARA, Fred Schaich spoke with Carl Dieffenbach about HIV prevention research presented at this year's International AIDS Conference and what the next prevention revolution is likely to be.
Gay and Bisexual Teen Males No More Likely Than Heterosexual Teen Males to Engage in Several Sexual Risk Behaviors; Still at Substantially Higher Risk of HIV Infection
New CDC data suggest there are no significant differences in several HIV-related risk behaviors among U.S. male students in ninth through 12th grades who identify as heterosexual, gay, or bisexual. Still, young gay and bisexual males are at much high...
This was "HIV vaccine day" at AIDS 2016, according to Carl Dieffenbach, Ph.D., since there were several important presentations about advances in ongoing HIV vaccine research.
For Mark S. King, the most stunning facet of the "Gay Day" International AIDS Pre-Conference was that so many of the gay men in attendance had the courage to show up at all.
A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent.
Three studies conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in rural and urban sub-districts of the KwaZulu-Natal province provide new insights into the engine that drives HIV transmission in the country. They a...
Zero: No Linked HIV Transmissions in PARTNER Study After Couples Had Sex 58,000 Times Without Condoms
The PARTNER study provides the strongest estimate of actual risk of HIV transmission when an HIV positive person has undetectable viral load -- and that this risk is effectively zero.
At ASM Microbe 2016, Dan H. Barouch, M.D., Ph.D., explained recent and upcoming studies involving two HIV cure strategies: therapeutic vaccines and broadly neutralizing antibodies.
Data from two large-scale dapivirine vaginal ring trials were reported at CROI 2016 and it works. Modestly. What's next?